CONVENIENCE TRANSLATION

INVITATION TO THE ANNUAL GENERAL MEETING

FRESENIUS SE & Co. KGaA
Bad Homburg v. d. H.

ISIN: DE0005785604 // WKN: 578560
ISIN: DE0005785620 // WKN: 578562
ISIN: DE000A169Q21 // WKN: A169Q2

We hereby invite our shareholders to the

Annual General Meeting

to be held on Friday, May 13, 2016, at 10 a.m. at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main.

Agenda

1. Presentation of the Annual Financial Statements and the Consolidated Financial Statements each approved by the Supervisory Board, the Management Reports for Fresenius SE & Co. KGaA and the Group and the Report of the Supervisory Board of Fresenius SE & Co. KGaA for the Fiscal Year 2015; Resolution on the Approval of the Annual Financial Statements of Fresenius SE & Co. KGaA for the Fiscal Year 2015

The Supervisory Board approved the annual financial statements drawn up by the General Partner and the consolidated financial statements pursuant to sec. 171 of the German Stock Corporation Act (Aktiengesetz). The annual financial statements are to be formally approved by the Annual General Meeting pursuant to sec. 286 para. 1 of the German Stock Corporation Act; the aforementioned documents are to be made available to the Annual General Meeting without the passing of any additional resolution being required.

The General Partner and the Supervisory Board propose that the annual financial statements of Fresenius SE & Co. KGaA for the fiscal year 2015 as presented, showing a distributable profit of Euro 300,198,550.02 be approved.
2. **Resolution on the Allocation of the Distributable Profit**

The General Partner and the Supervisory Board propose to allocate the distributable profit of Fresenius SE & Co. KGaA in the amount of Euro 300,198,550.02, shown in the annual financial statements for the fiscal year 2015, as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payment of a dividend of Euro 0.55 per share</td>
<td>Euro 300,150,372.50</td>
</tr>
<tr>
<td>on the 545,727,950 shares entitled to a dividend</td>
<td></td>
</tr>
<tr>
<td>The dividend is payable on May 16, 2016.</td>
<td>Euro 48,177.52</td>
</tr>
<tr>
<td>Balance to be carried forward</td>
<td>Euro 300,198,550.02</td>
</tr>
</tbody>
</table>

The number of shares entitled to a dividend rights may change prior to the General Meeting. In such cases, an appropriately adjusted proposal for the resolution on the allocation of the distributable profit shall be put to the General Meeting, based on an unchanged distribution of Euro 0.55 per share entitled to a dividend.

3. **Resolution on the Approval of the Actions of the General Partner for the Fiscal Year 2015**

The General Partner and the Supervisory Board propose to approve the actions of the General Partner for the fiscal year 2015.

4. **Resolution on the Approval of the Actions of the Supervisory Board for the Fiscal Year 2015**

The General Partner and the Supervisory Board propose to approve the actions of the members of the Supervisory Board of the Company for the fiscal year 2015.


Upon recommendation of its Audit Committee, the Supervisory Board proposes to elect KPMG AG Wirtschaftsprüfungsgesellschaft, Berlin, as the auditor and group auditor for the fiscal year 2016 and as the auditor for the potential review of the half-yearly financial report for the first half-year of the fiscal year 2016 and other financial information according to sec. 37w para. 7 German Securities Trading Act (WpHG), which are prepared before the Annual General Meeting 2017.

6. **Election to the Supervisory Board**

Pursuant to secs. 95 and 96 of the German Stock Corporation Act, sec. 22 in conjunction with secs. 24 and 25 of the Co-Determination of Employees in Cross-Border Mergers Act (MgVG) and Article 8 (1) and (2) of the Articles of Association, the Supervisory Board of Fresenius SE & Co. KGaA comprises six representatives each from the shareholders and the employees. Pursuant to sec. 96 para. 3 sent. 1 of the German Stock Corporation Act, the Supervisory Board must contain at least 30 percent male and female members, whereby pursuant to sec. 96 para. 2 sent. 2 in conjunction with sec. 96 para. 3 sent. 2 of the German Stock Corporation Act, the minimum share is to be fulfilled by the Supervisory Board overall.
The election of six shareholder representatives is necessary because, in accordance with Article 8 (3) of Articles of Association pursuant to resolution of the Annual General Meetings for 2010 and 2015, the period of office of the shareholder representatives ends upon the close of this year’s Annual General Meeting.

Upon the recommendation of the Nomination Committee, the Supervisory Board proposes that, with effect as of the end of this Annual General Meeting until the end of the Annual General Meeting which resolves on the ratification of the actions of the Supervisory Board for the fourth fiscal year after the term of office commenced, that the following individuals be elected to the Supervisory Board as shareholder representatives. The year in which the period of office commences shall not count.

a) Prof. Dr. med. D. Michael Albrecht, Medical director and spokesman of the Management Board of the Universitätsklinikum Carl Gustav Carus Dresden, resident in Dresden
Prof. Dr. med. D. Michael Albrecht holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
GÖK Consulting AG
Universitätsklinikum Aachen

b) Mr. Michael Diekmann, former Chairman of the Management Board of Allianz SE, resident in Munich
Mr. Michael Diekmann holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
BASF SE (Deputy Chairman)
Fresenius Management SE (since May 20, 2015)
Linde AG (Deputy Chairman)
Siemens AG

Board of Directors
Allianz Australia Ltd (Non-Executive Director)

c) Dr. Gerd Krick, former Chairman of the Management Board Fresenius AG, resident in Königstein
Dr. Gerd Krick holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
Fresenius Management SE (Chairman)
Fresenius Medical Care AG & Co. KGaA (Chairman)
Fresenius Medical Care Management AG
VAMED AG, Österreich (Chairman)
d) Prof. Dr. med. Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President, Head of Development and Medical Patient Value Practices of UCB S.A., Belgium, resident in Ratingen
Prof. Dr. med. Iris Löw-Friedrich holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
Evotec AG

e) Mr. Klaus-Peter Müller, Chairman of the Supervisory Board of Commerzbank AG, resident in Bad Homburg v. d. H.
Mr. Klaus-Peter Müller holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
Commerzbank AG (Chairman)
Fresenius Management SE

Board of Directors
Parker Hannifin Corporation, USA

f) Ms. Hauke Stars, Member of the Management Board of Deutsche Börse AG, resident in Königstein
Ms. Hauke Stars holds official posts on statutory supervisory boards or comparable domestic or international control bodies of the following companies:

Supervisory Board
Eurex Frankfurt AG
GfK SE
Klöckner & Co SE

Board of Directors
Eurex Zürich AG

Ms. Hauke Stars has declared, that her official posts on the supervisory boards of GfK SE and Klöckner & Co SE will end in May 2016.

The Supervisory Board is of the opinion that there shall be no business or personal relations that are to be disclosed pursuant to sec. 5.4.1 of the German Corporate Governance Code at the point in time of the General Meeting of Fresenius SE & Co. KGaA on May 13, 2016.

In the event that he is elected to the Supervisory Board, Dr. Gerd Krick has expressed his intention to stand for the post of Chairman. In the event that he is elected to the Supervisory Board, Mr. Michael Diekmann has expressed his intention to stand for the post of Deputy Chairman.
The elections shall be held on an individual basis. Prof. Dr. med. Iris Löw-Friedrich and Frau Hauke Stars are proposed as new members. The remaining nominees are already members of the Supervisory Board and will be proposed for reappointment.

Further information on the candidates can be found in the attachment “Other disclosures regarding agenda items 6 and 7” as well as on the Company’s website at www.fresenius.de under Investors/Annual General Meeting.

7. Election to the Joint Committee

Article 13a of the Articles of Association of the Company stipulates that the Company shall have a Joint Committee that will be made up of two members of the Supervisory Board appointed by the General Partner and two members of the Supervisory Board of the Company (Joint Committee).

The election of two new members from the Supervisory Board of the Company is required because, in accordance with Article 13b (4) in conjunction with Article 8 (3) of the Articles of Association pursuant to resolution of the Annual General Meetings for 2011 and 2015, the term of office of the representatives from the Supervisory Board of the Company ends upon the close of this year’s Annual General Meeting.

Pursuant to Article 13b (4) and Article 8 (3) of the Articles of Association, the Supervisory Board proposes to elect to the Joint Committee

Mr. Michael Diekmann, former Chairman of the Management Board of Allianz SE, resident in Munich and

Dr. Gerd Krick, former Chairman of the Management Board Fresenius AG, resident in Königstein

with effect as of the end of this Annual General Meeting until the end of the Annual General Meeting which resolves on the ratification of the actions for the fourth fiscal year after the term of office commenced. The year in which the period of office commences shall not count.

Further information on Mr. Michael Diekmann and Dr. Gerd Krick is set forth in agenda item 6 and in the attachment “Other disclosures regarding agenda items 6 and 7” as well as on the Company’s website at www.fresenius.de under Investors/Annual General Meeting.
Total Number of Shares and Voting Rights

At the time the Annual General Meeting is convened, 545,810,836 shares out of a total of 545,810,836 shares issued carry participation rights and voting rights.

Participation in the Annual General Meeting and Exercise of Voting Rights

Shareholders who wish to participate in the Annual General Meeting or to exercise their voting rights must register for the Annual General Meeting and prove their eligibility.

The registration and proof of eligibility must be received by the Company at

Fresenius SE & Co. KGaA  
c/o Deutsche Bank AG  
Securities Production  
General Meetings  
Postfach 20 01 07  
60605 Frankfurt am Main

Fax no.: +49 (0) 69 / 12 012-86 045  
E-mail: WP.HV@db-is.com

at least 6 days prior to the Annual General Meeting, i.e. no later than May 6, 2016, 24:00 hours CEST. For the purpose of proving eligibility, a special proof of share ownership issued by the custodian in writing (Textform) in the German or English language is sufficient. The proof of share ownership has to relate to the start of April 22, 2016, i.e. 0:00 hours CEST (record date). The shareholder or his authorized representative shall receive an admission ticket for the Annual General Meeting against submission of the proof of share ownership.

In relation to the Company, a shareholder will only be deemed a shareholder entitled to participate in the Meeting and to exercise voting rights if the shareholder has submitted the special proof of share ownership. The entitlement to participate in the Meeting and the scope of the voting rights are exclusively determined by the proven shares owned on the record date. The record date shall not result in a blocking period during which it is not allowed to sell shares. Even in the event of a full or partial sale of the shareholding following the record date, only the shares owned by the shareholder on the record date will be relevant for participation in the Meeting and the scope of the voting rights, i.e. a sale of shares, if any, after the record date will not affect entitlement to participate in the Meeting and the scope of the voting rights. This also applies mutatis mutandis if (additional) shares are purchased after the record date. Persons who do not own any shares on the record date, and become shareholders only after the record date, are not entitled to participate in the Meeting and to exercise voting rights. The record date does not constitute a relevant date with respect to the entitlement to dividends.

Each share grants one vote in the Annual General Meeting.
Voting Procedure

Voting by proxies

A shareholder may also instruct an authorized representative, e.g. the custodian bank, an association of shareholders or any other person of his choice, to exercise his voting right in the Annual General Meeting. A registration of the shareholder, including proof of share ownership, in due time in accordance with the aforesaid will also be necessary in case of a voting by proxy.

Pursuant to sec. 134 para. 3 in conjunction with sec. 134 para. 3 of the German Stock Corporation Act, the power of attorney must be granted and revoked, and the authorization evidenced, to the Company in writing (Textform) (sec. 126b German Civil Code (Bürgerliches Gesetzbuch). Shareholders wishing to authorize a proxy should use the form of the power of attorney they will receive together with the admission ticket. The power of attorney respectively the evidence of the authorization must either be presented on the day of the Annual General Meeting or be sent to the Company at the following address:

Fresenius SE & Co. KGaA
Investor Relations
C/o Computershare Operations Center
80249 Munich
Fax no.: +49 (0) 89 / 30 90 37-46 75
E-mail: FreseniusSE-HV2016@computershare.de

For organizational reasons, if the power of attorney or the proof of the power of attorney is submitted to the Company in advance at the postal address, fax number or e-mail address stated above, we request that this be done by 6 p.m. CEST on Wednesday, May 11, 2016.

Pursuant to Article 15 (4) (3) of the Articles of Association, it is determined that a power of attorney can be revoked by appearing in person at the Annual General Meeting.

If the power of attorney is granted to a credit institution or any other individual, association of shareholders or institution treated as equivalent to the aforesaid pursuant to sec. 135 para. 8 and para. 10 in conjunction with sec. 125 para. 5 of the German Stock Corporation Act and sec. 278 para. 3 of the German Stock Corporation Act, in general, particularities are to be considered which are to be requested from the respective authorized proxy. Pursuant to sec. 135 para. 1 sent. 2 of the German Stock Corporation Act, the power of attorney must be kept by the proxy in a verifiable form. Such power of attorney must be complete and may only contain declarations associated with the exercise of voting rights. Shareholders wishing to issue a proxy authorization to a credit institution, an association of shareholders or any other individual or institution treated as equivalent to the aforesaid are requested to reach agreement with the same on the form of the power of attorney.

Voting by Company proxies

In addition, in advance of the Annual General Meeting, the Company offers its shareholders the possibility of authorizing Company-nominated employees, who are bound by instructions given to them (weisungsgebun-
dene Stimmrechtsvertreter), as proxies for the exercise of voting rights. Those shareholders who wish to grant a power of attorney to the proxies nominated by the Company also have to register for the Annual General Meeting and prove their eligibility as aforesaid. The power of attorney and the instructions to the proxies nominated by the Company shall be in writing (Textform) and must be granted by using the form the shareholders receive together with the admission ticket to the Annual General Meeting. The completed form may also be submitted to the Company prior to the Annual General Meeting at the following address:

Fresenius SE & Co. KGaA
Investor Relations
c/o Computershare Operations Center
80249 Munich
Fax no.: +49 (0) 89 / 30 90 37-4675
E-mail: FreseniusSE-HV2016@computershare.de

In this case, for organizational reasons, the form must be received by the Company by 6 p.m. CEST on Wednesday, May 11, 2016, at the postal address, fax number or e-mail address stated above. This does not affect the option of authorizing the Company-nominated proxies during the course of the Annual General Meeting.

The Company proxies are to vote in accordance with the instructions issued by the shareholders. If no instructions are issued, the power of attorney shall be invalid. Please note that the proxies are unable to accept any authority or instructions for exercising the right to speak and to ask questions, to submit motions or to file objections against shareholders’ resolutions adopted at the Annual General Meeting and that proxies will always abstain from voting in respect of resolutions proposed by shareholders during the Annual General Meeting which have not been announced prior to the Annual General Meeting.

Shareholder Rights

Motions by shareholders to amend the agenda pursuant to sec. 122 para. 2 in conjunction with sec. 278 para. 4 of the German Stock Corporation Act

Shareholders whose aggregate shareholding equals or exceeds 5% of the share capital or a pro-rata amount of Euro 500,000 may request that items be included in the agenda and published. Any such request must be made in writing to:

Fresenius SE & Co. KGaA
Management Board of the General Partner
Fresenius Management SE
Attn. Dr. Jürgen Götz
Else-Kröner-Strasse 1
61352 Bad Homburg v.d. H.

The request must be received by the Company at the above address at least 30 days prior to the Annual General Meeting, i.e. the request must be received by April 12, 2016, 24:00 hours CEST. Each new item must be substantiated or accompanied by a proposal for resolution.
Motions and election proposals by shareholders pursuant to secs. 126 para. 1 and 127 of the German Stock Corporation Act in conjunction with sec. 278 para. 4 of the German Stock Corporation Act

Shareholders may submit motions on the individual items of the agenda (cf. sec. 126 para. 2 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act); this shall also apply to proposals for the election of members of the Supervisory Board or of auditors (cf. sec. 127 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act).

Pursuant to sec. 126 para. 1 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act, motions by shareholders, including the shareholder’s name, a statement of grounds for the motion and any comments by the Management, if any, are to be made available to the relevant authorized persons listed in sec. 125 paras. 1 to 3 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act (as for example shareholders, among others who so request) in accordance with the conditions set forth therein, provided that the shareholder has sent a counter motion opposed to a proposal of the General Partner and/or the Supervisory Board in respect of a certain agenda item, including a statement of grounds for the counter motion, to the Company at the address set forth below, no later than 14 days prior to the Annual General Meeting, i.e. the counter motion must be received by April 28, 2016, 24:00 hours CEST. The aforementioned information must be made available via the Company’s website. A counter motion need not be made available if one of the exceptions pursuant to sec. 126 para. 2 of the German Stock Corporation Act in conjunction with sec. 278 para. 4 of the German Stock Corporation Act applies. The statement of grounds need not be made available if it exceeds a total of 5,000 characters.

The right of each shareholder to make counter motions regarding the various agenda items during the Annual General Meeting without advance communication to the Company remains unaffected. Please note that any counter motions which have been sent to the Company in advance and in due time will only be considered in the Annual General Meeting if they are submitted orally during the Meeting.

No statement of grounds need be provided for election proposals made by shareholders pursuant to sec. 127 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act. Election proposals need not be made available by the General Partner if they do not contain the name, the exercised profession and the place of residence of the nominees and, in case of an election of members of the Supervisory Board, information on their membership in other supervisory boards, the constitution of which is required under existing law (cf. sec. 127 sent. 3 in conjunction with sec. 124 para. 3 sent. 3 and sec. 125 para. 1 sent. 5 of the German Stock Corporation Act in conjunction with sec. 278 para. 3 of the German Stock Corporation Act). Pursuant to sec. 127 sent. 1 in conjunction with sec. 126 para. 2 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act, there are further circumstances under which election proposals do not need to be made available via the website. In all other respects, the requirements and provisions for making motions available apply mutatis mutandis.

Motions and election proposals by shareholders pursuant to secs. 126 para. 1 and 127 of the German Stock Corporation Act in conjunction with sec. 278 para. 3 of the German Stock Corporation Act shall be sent exclusively to:
Any motions and election proposals of shareholders which are to be made available will be published in accordance with the aforesaid conditions on the Company’s website at www.fresenius.com under Investors/Annual General Meeting. Comments of the management, if any, will also be published on that website.

Information right pursuant to sec. 131 para. 1 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act.

At the Annual General Meeting, the General Partner shall, upon request, provide each shareholder with information regarding the matters of the Company to the extent such information is necessary for a proper evaluation of the relevant item on the agenda (cf. sec. 131 para. 1 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act). The General Partner’s duty to provide information also extends to the Company’s legal and business relationships with any affiliated company as well as to the situation of the Group and the companies included in the consolidated financial statements. Any request for information must, in principle, be submitted orally at the Annual General Meeting during the course of discussion.

The information shall comply with the principles of conscientious and accurate accountability. The General Partner may refuse to provide information under the conditions set forth in sec. 131 (3) in conjunction with sec. 278 para. 3 of the German Stock Corporation Act. Pursuant to Article 17 (2) of the Articles of Association, the chairman of the Meeting may reasonably restrict the time granted to shareholders within the scope of their right to ask questions and to speak; in particular, he shall have the right to determine a reasonable time frame for the conduct of the Annual General Meeting, for individual agenda items, or for individual speakers either at the beginning or during the Annual General Meeting.

Annual General Meeting Documents

As of the day of publication of this invitation, the following documents will be available, together with this notice, for inspection by the shareholders at the offices of Fresenius SE & Co. KGaA (Else-Kröner-Strasse 1, 61352 Bad Homburg v.d.H.):

- Financial statements of Fresenius SE & Co. KGaA for the year ended December 31, 2015, approved by the Supervisory Board
- Management Report of Fresenius SE & Co. KGaA for the fiscal year 2015
- Consolidated financial statements of Fresenius SE & Co. KGaA in accordance with IFRS for the year ended December 31, 2015, approved by the Supervisory Board
- Consolidated Management Report of Fresenius SE & Co. KGaA in accordance with IFRS for the fiscal year 2015
The above documents will also be made available at the Annual General Meeting of the Company.

Publications on the Website

The information pursuant to sec. 124a in conjunction with sec. 278 para. 3 of the German Stock Corporation Act regarding the Annual General Meeting (among other things, the invitation, documents to be made available, forms of proxy and for issuing instructions, applications by shareholders, if applicable) as well as further explanations concerning the rights of shareholders pursuant to sec. 122 para. 2 in conjunction with sec. 278 para. 3 of the German Stock Corporation Act, are made available to shareholders on the Company’s website at www.fresenius.com under Investors/Annual General Meeting. It is intended to broadcast the speech of the Chairman of the Management Board in audio and video form on the Internet.

Bad Homburg v. d. H., March 2016

Fresenius SE & Co. KGaA

The General Partner
Fresenius Management SE
The Management Board
Attachment "Other disclosures regarding agenda items 6 and 7"

DETAILLED CVS
a) Prof. Dr. med. D. Michael Albrecht

Medical Director and Spokesman of the Management Board
University Hospital Carl Gustav Carus Dresden

Member of the Supervisory Board of Fresenius SE & Co. KGaA since 2011

Date of Birth: December 14, 1949
Place of Birth: Munich
Nationality: German

**Professional Experience**

since 2002 University Hospital Carl Gustav Carus Dresden
Medical Director and Spokesman of the Management Board

1999 – 2002 Technical University of Dresden
Dean of the Faculty of Medicine

1997 – 1999 Harvard Medical International Association Institution Dresden
Director, founder and dean

1994 – 1997 Technical University of Dresden
Appointment as a C4-Professor in anesthesiology and intensive care

1989 – 1994 University of Heidelberg
  ▶ 1992 – 1994 Director and Founder Center for Medical Research
  ▶ 1989 – 1992 appointment as C3-Professor for anesthesiology; Deputy Medical Director of the clinic for anesthesiology and intensive care

**Education**

1989 University of Lübeck
Habilitation in medicine (Prof. Dr. med.)

1985 LMU Munich
Doctorate in medicine (Dr. med.)

1971 – 1976 LMU Munich
Studies of medicine

**Membership of other statutory supervisory boards**

GÖK Consulting AG
University Hospital Aachen

**Membership of comparable German or foreign supervisory bodies**

None

The Fresenius Group maintains business relations with the University Hospital Carl Gustav Carus Dresden and the University Hospital Aachen in the ordinary course of business under customary conditions. In the fiscal year 2015, the total transaction volume with the University Hospital Carl Gustav Carus was equivalent to 0.03% of the Group sales of Fresenius SE & Co. KGaA and the total transaction volume with the University Hospital Aachen was equivalent to 0.009% of the Group sales of Fresenius SE & Co. KGaA.
b) Michael Diekmann

Former Chairman of the Management Board/CEO of Allianz SE
Deputy Chairman of the Supervisory Board of Fresenius SE & Co. KGaA since 2015

Date of Birth: December 23, 1954
Place of Birth: Bielefeld
Nationality: German

Professional Experience

2003 – 2015 Allianz SE (formerly Allianz AG)
Chairman of the Management Board

1998 – 2003 Allianz AG
Member of the Management Board

1988 – 1998 Allianz Versicherungs-AG

1983 – 1988 Diekmann/Thieme GbR (publishing house)
CEO

Education

1973 – 1982 University of Göttingen
Studies in Law and Philosophy

Membership of other statutory supervisory boards

BASF SE (Deputy Chairman of the Supervisory Board)
Fresenius Management SE
Linde AG (Second Deputy Chairman of the Supervisory Board)
Siemens AG

Membership of comparable German or foreign supervisory bodies

Allianz Australia Ltd. (Non-Executive Director)
Dr. Gerd Krick

Former Chairman of the Management Board of Fresenius AG
Chairman of the Supervisory Board of Fresenius SE & Co. KGaA since 2003

Date of Birth: October 8, 1938
Place of Birth: Dresden
Nationality: Austrian

Professional Experience

1975 – 2003 Fresenius AG
   ▶ 1992 – 2003 Chairman of the Management Board
   ▶ 1981 – 1992 Member of the Management Board responsible for Medical Devices Division
   ▶ 1975 – 1981 Managing Director for Research & Development, Production & Technology

   Director and Limited Partner

1970 Continental AG
   Assistant to the Management Board Member responsible for Research & Development

Education

1965 – 1971 Technical University of Munich
   Doctorate in mechanical engineering (Dr. Ing.)

1961 – 1965 Technical University of Munich
   Studies in mechanical engineering

Membership of other statutory supervisory boards

Fresenius Management SE (Chairman)
Fresenius Medical Care AG & Co. KGaA (Chairman)
Fresenius Medical Care Management AG
VAMED AG, Österreich (Chairman)

Membership of comparable German or foreign supervisory bodies

None
d) Prof. Dr. med. Iris Löw-Friedrich

Chief Medical Officer and Executive Vice President, Head of Development and Medical Patient Value Practices, UCB S.A.

Date of Birth: November 17, 1960
Place of Birth: Offenbach/Main
Nationality: German

Professional Experience

2008 – today UCB S.A.
   Chief Medical Officer and Executive Vice President Development

2001 – 2009 Schwarz Pharma AG
   Member of the Executive Board, Head of Research and Development

2000 – 2001 BASF Pharma
   Vice President Global Projects

1992 – 2000 Hoechst AG
   Various positions, last serving as Vice President Clinical Development

Education

since 2000 University of Frankfurt am Main
   Professor for internal medicine

1985 University of Frankfurt am Main
   Doctorate in medicine (Dr. med.)

1979 – 1985 University of Frankfurt am Main
   Studies of medicine

Membership of other statutory supervisory boards

Evotec AG

Membership of comparable German or foreign supervisory bodies

None
e) Klaus-Peter Müller

Chairman of the Supervisory Board Commerzbank AG

Member of the Supervisory Board of Fresenius SE & Co. KGaA since 2008

Date of Birth: September 16, 1944
Place of Birth: Duppach
Nationality: German

Professional Experience

1990 – 2008 Commerzbank AG
▶ 2001 – 2008 Chairman of the Management Board
▶ 1990 – 2001 Member of the Management Board

1966 – 1990 Commerzbank AG
▶ Head of the department in charge of the bank’s East German operations
▶ Executive Vice President/Head of corporate banking department
▶ Joint Manager of the New York branch
▶ Düsseldorf branch, later Joint Manager of the Duisburg branch
▶ Representative office (later branch) in New York
▶ Düsseldorf branch

Education

1964 – 1966 Military service (1st Lt.)

1962 – 1964 Bankhaus Friedrich Simon KGaA
Apprenticeship in banking

Membership of other statutory supervisory boards

Commerzbank AG (Chairman)
Fresenius Management SE

Membership of comparable German or foreign supervisory bodies

Parker Hannifin Corporation

The Fresenius Group maintains business relations with Commerzbank AG in the ordinary course of business under customary conditions. In the fiscal year 2015 the total transaction volume with Commerzbank AG was equivalent to 0.001% of the Group sales of Fresenius SE & Co. KGaA.
f) Hauke Stars

Member of the Executive Board Deutsche Börse AG

Date of Birth: June 3, 1967
Place of Birth: Merseburg
Nationality: German

Professional Experience

since 2012  Deutsche Börse AG
Member of the Executive Board
▶ since 2016  responsible for Cash Market, Pre-IPO & Growth Financing
▶ 2012 – 2015  responsible for the Information Technology and
Market Data + Services Division

2004 – 2012  Hewlett Packard AG
Last position: Managing Director Switzerland and Country Manager Enterprise Business

1998 – 2004  Triaton GmbH
(formerly ThyssenKrupp Information System GmbH)
Last position: Senior Vice President Sales and Marketing
Member of Triaton Management Board

Last Position: Executive Assistant to the CIO of Bertelsmann AG

Education

1991 – 1992  University of Warwick (UK)
MSc by Research in Engineering

Engineering degree in applied computer science (Dipl.-Ing.)

Membership of other statutory supervisory boards

Eurex Frankfurt AG (Deutsche Börse Group mandate)
GfK SE (ends in May 2016)
Klöckner & Co. SE (ends in May 2016)

Membership of comparable German or foreign supervisory bodies

Eurex Zürich AG, Member of the Board of Directors (Deutsche Börse Group mandate)

Ms. Hauke Stars has declared, that her official posts on the supervisory boards of GfK SE and Klöckner & Co SE will end in May 2016.

The Fresenius Group maintains business relations with Deutsche Börse AG in the ordinary course of business under customary conditions. In the fiscal year 2015 the total transaction volume with Deutsche Börse AG was equivalent to 0.0001 % of the Group sales of Fresenius SE & Co. KGaA.